Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
China Bozza Development Holdings Limited ( (HK:1069) ) has issued an announcement.
China Health Technology Group Holding Company Limited has reported its unaudited condensed consolidated interim results for the six months ending December 31, 2024. The company experienced a significant decline in profit compared to the previous period, with a profit of RMB 4,978,000, down from RMB 201,421,000. This decline is primarily due to the absence of a gain on debt restructuring, which had a substantial impact on the previous period’s results. The revenue increased to RMB 31,112,000 from RMB 19,020,000, but the cost of sales also rose, leading to a reduced gross profit. The company’s comprehensive income for the period was RMB 6,353,000, reflecting a decrease from the previous period.
More about China Bozza Development Holdings Limited
YTD Price Performance: -2.50%
Average Trading Volume: 2,066,436
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$33.51M
For detailed information about 1069 stock, go to TipRanks’ Stock Analysis page.